Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell ...
Creative Medical Technology Holdings, Inc. reported a 93% response rate in its Ultrasome knee osteoarthritis program, demonstrating clinically meaningful improvements in mobility and pain reduction. The company's proprietary cell-free regenerative therapy is derived from its GMP-manufactured cell therapy product CELZ-201.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced positive results from its Ultrasome pilot study for knee osteoarthritis treatment. The study achieved its primary endpoint with 93% of patients showing improvements in mobility and pain reduction. Ultrasome is derived from the company's GMP-manufactured cell therapy product CELZ-201. The therapy was well-tolerated with no serious adverse events reported. Creative Medical plans to expand the Ultrasome program and generate additional clinical data. Osteoarthritis affects over 30 million adults in the United States, representing a significant multi-billion-dollar opportunity.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.